GSK has a patent lawsuit from Sandoz on Lovaza and a ruling is expected in the next 30-45 days. If GSK loses patent, how does this affect AMRN? Do managed care companies restrict AMRN product for those that fail first on a cheaper generic Lovaza? I know a lot has to do with the AMRN label from FDA upon approval and any insights on the difference in the label would be appreciated. Does GSK become an aggressive bidder of AMRN?